Next Article in Journal
Patterns of Autologous and Nonautologous Interactions between Core Nuclear Egress Complex (NEC) Proteins of α-, β- and γ-Herpesviruses
Previous Article in Journal
User-Friendly Reverse Genetics System for Modification of the Right End of Fowl Adenovirus 4 Genome
Open AccessMeeting Report

The Beginning of Ending Hepatitis C Virus: A Summary of the 26th International Symposium on Hepatitis C Virus and Related Viruses

1
Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Korea
2
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea
3
Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan
4
Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon 34114, Korea
5
Unit of Viral Hepatitis, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China
6
University of Chinese Academy of Sciences, Beijing 100049, China
7
Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam 13488, Korea
8
Division of Gastroenterology and Hepatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Korea
9
Department of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, Korea
10
Applied Molecular Virology Laboratory, Institut Pasteur Korea, Seongnam 13488, Korea
11
Department of Biotechnology, Yonsei University, Seoul 03722, Korea
12
Department of Life Sciences, Pohang University of Science and Technology, Pohang 37673, Korea
*
Author to whom correspondence should be addressed.
Viruses 2020, 12(3), 302; https://doi.org/10.3390/v12030302
Received: 6 March 2020 / Accepted: 10 March 2020 / Published: 11 March 2020
Hepatitis C virus (HCV) infects ~71 million people worldwide, and 399,000 people die annually due to HCV-related liver cirrhosis and hepatocellular carcinoma. The use of direct-acting antivirals results in a sustained virologic response in >95% of patients with chronic HCV infection. However, several issues remain to be solved to eradicate HCV. At the 26th International Symposium on Hepatitis C Virus and Related Viruses (HCV2019) held in Seoul, South Korea, October 5–8, 2019, virologists, immunologists, and clinical scientists discussed these remaining issues and how we can achieve the elimination of HCV. View Full-Text
Keywords: hepatitis C virus; antivirals; vaccine; flavivirus; liver diseases hepatitis C virus; antivirals; vaccine; flavivirus; liver diseases
MDPI and ACS Style

Shin, E.-C.; Han, J.W.; Kang, W.; Kato, T.; Kim, S.-J.; Zhong, J.; Kim, S.; Park, S.-H.; Sung, P.S.; Watashi, K.; Park, J.Y.; Windisch, M.P.; Oh, J.-W.; Wakita, T.; Han, K.-H.; Jang, S.K. The Beginning of Ending Hepatitis C Virus: A Summary of the 26th International Symposium on Hepatitis C Virus and Related Viruses. Viruses 2020, 12, 302.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop